The long and winding road to gut homeostasis

Current Opinion in Gastroenterology

Volumn 22, Issue 4, 2006, Pages 349-353

  Arulampalam, Velmurugesan ^a   Greicius, Gediminas ^a   Pettersson, Sven ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Commensal bacteria; Gut homeostasis; Inflammation; Nuclear receptors

Indexed keywords

CELL NUCLEUS RECEPTOR; CYCLOOXYGENASE 2 INHIBITOR; FARNESOID X RECEPTOR; NIMESULIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TROGLITAZONE; VITAMIN D RECEPTOR;

ADIPOCYTE; BACTERIAL INFECTION; BACTERIAL STRAIN; CARCINOGENESIS; CHEMICAL ANALYSIS; COLON CANCER; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM INFLAMMATION; DNA POLYMORPHISM; GENE TRANSLOCATION; HOMEOSTASIS; HUMAN; INTESTINE; MICROORGANISM; NONHUMAN; OBESITY; REVIEW; STATISTICAL SIGNIFICANCE; SYMBIOSIS;

ANIMALS; BACTERIA; DISEASE PROGRESSION; GASTROINTESTINAL TRACT; HOMEOSTASIS; HUMANS; INFLAMMATORY BOWEL DISEASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 33746263877     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000231806.65030.ed     Document Type: Review

References (49)

1. Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006; 6:9-20.
2. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
3. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-606.
4. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003; 124:1265-1276.
5. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev 2001; 81:1269-1304.
6. Wang Q, Herrera-Ruiz D, Mathis AS, et al. Expression of PPAR, RXR isoforms and fatty acid transporting proteins in the rat and human gastrointestinal tracts. J Pharm Sci 2005; 94:363-372.
7. Mansen A, Guardiola-Diaz H, Rafter J, et al. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 1996; 222:844-851.
8. Heimerl S, Moehle C, Zahn A, et al. Alterations in intestinal fatty acid metabolism in inflammatory bowel disease. Biochim Biophys Acta 2006; 1762:341-350.
9. Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 2006; 103:3920-3925. Farnesoid X receptor is shown to modulate bile acid-induced protection of the epithelial barrier. A general immunoprotective role for bile acids in the intestine is envisaged.
10. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004; 3:950-964.
11. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004; 5:104-112.
12. Viboud GI, Bliska JB. Yersinia outer proteins: role in modulation of host cell signaling responses and pathogenesis. Annu Rev Microbiol 2005; 59:69-89.
13. Palmer LE, Hobbie S, Galan JE, et al. YopJ of Yersinia pseudotuberculosis is required for the inhibition of macrophage TNF-alpha production and down-regulation of the MAP kinases p38 and JNK. Mol Microbiol 1998; 27:953-965.
14. Ernst JD. Bacterial inhibition of phagocytosis. Cell Microbiol 2000; 2:379-386.
15. Genolet R, Wahli W, Michalik L. PPARs as drug targets to modulate inflammatory responses? Curr Drug Targets lnflamm Allergy 2004; 3:361-375.
16. Katayama K, Wada K, Nakajima A, et al. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 2003; 124:1315-1324.
17. Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001; 193:827-838.
18. Sugawara K, Olson TS, Moskaluk CA, et al. Linkage to peroxisome proliferator-activated receptor-gamma in SAMP1/YitFc mice and in human Crohn's disease. Gastroenterology 2005; 128:351-360.
19. Takagi T, Naito Y, Tomatsuri N, et al. Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappaB-cytokine cascade. Redox Rep 2002; 7:283-289.
20. Kohno H, Suzuki R, Sugie S, Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 2005; 5:46.
21. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999; 104:383-389.
22. Sanchez-Hidalgo M, Martin AR, Villegas I, et al. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol 2005; 69:1733-1744.
23. Lytle C, Tod TJ, Vo KT, et al. The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis 2005; 11:231-243.
24. Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 2004; 127:777-791.
25. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med 2005; 201:1205-1215. This paper demonstrates that 5-aminosalicylic acid, long used in IBD treatment, is a PPARγ ligand. This agonist is also shown to activate expression of PPARγ, a feature which is very important in lesions where expression of this receptor is impaired.
26. Froicu M, Zhu Y, Cantorna MT. Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology 2006; 117:310-318. A new player, VDR, is confirmed to be a potent anti-inflammatory factor in regulating gastrointestinal immunity. A possibility for VDR in mediating immunity to commensal bacteria is also raised in this paper.
27. Joseph SB, Castrillo A, Laffitte BA, et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9:213-219.
28. Castrillo A, Joseph SB, Vaidya SA, et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 2003; 12:805-816.
29. Joseph SB, Bradley MN, Castrillo A, et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 2004; 119:299-309.
30. Valledor AF, Hsu LC, Ogawa S, et al. Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc Natl Acad Sci U S A 2004; 101:17813-17818.
31. Ogawa S, Lozach J, Benner C, et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005; 122:707-721. This is an exploration of how nuclear receptors regulate immunity has led to the notion that different nuclear receptors can modulate inflammation, using overlapping but distinct sets of response genes. This study also raised the issue of using combinatorial nuclear receptor therapy as a possible remedy in treating chronic inflammatory diseases.
32. Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 2005; 307:1904-1909.
33. Nathke IS. The adenomatous polyposis coli protein: the Achilles heel of the gut epithelium. Annu Rev Cell Dev Biol 2004; 20:337-366.
34. Jansson EA, Are A, Greicius G, et al. The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells. Proc Natl Acad Sci U S A 2005; 102:1460-1465.
35. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev 2005; 26:898-915.
36. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4:1046-1052.
37. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998; 4:1058-1061.
38. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998; 4:1053-1057.
39. Girnun GD, Smith WM, Drori S, et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA 2002; 99:13771-13776.
40. Knutsen HK, Olstorn HB, Paulsen JE, et al. Increased levels of PPARbeta/delta and cyclin D1 in flat dysplastic ACF and adenomas in Apc(Min/+) mice. Anticancer Res 2005; 25:3781-3789.
41. Harman FS, Nicol CJ, Marin HE, et al. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med 2004; 10:481-483.
42. Gupta RA, Wang D, Katkuri S, et al. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 2004; 10:245-247.
43. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101:15718-15723.
44. Kersten S, Mandard S, Tan NS, et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem 2000; 275:28488-28493.
45. Le Jan S, Amy C, Cazes A, et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 2003; 162:1521-1528.
46. Mookherjee N, Brown KL, Bowdish DM, et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 2006; 176:2455-2464. In this paper the anti-inflammatory properties of the defence peptide LL-37 are proposed to contribute to homeostasis through interacting with TLR induced pathways. Interestingly, other studies have shown that VDR can affect expression of LL-37.
47. Heilborn JD, Nilsson MF, Kratz G, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 2003; 120:379-389.
48. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. Faseb J 2005; 19:1067-1077.
49. Froicu M, Weaver V, Wynn TA, et al. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 2003; 17:2386-2392.